Immunogenincwas A Clinical Stage Biotechnology Company Based In Walthammassachusettsspecializing In Antibody Drug Conjugatesadcsfor Targeted Cancer Therapiesfounded In 1981The Company Focused On Developing Adcs That Combine Monoclonal Antibodies With Cytotoxic Agents To Selectively Target And Kill Cancer Cellsminimizing Harm To Healthy Tissues The Companyae S Notable Productelaherea Mirvetuximab Soravtansine Gynx Is Fda Approved For Treating Folate Receptor Alpha Positiveplatinum Resistant Ovarian Cancerimmunogen Also Developed Other Adcsincluding Pivekimab Sunirine For Acute Myeloid Leukemia And Imgc936 For Solid Tumorsthe Company Collaborated With Major Pharmaceutical Firms Like Rocheamgenand Novartis To Enhance Its Adc Therapies In November 2023Immunogen Was Acquired By Abbvie For $10 1 Billionbecoming A Subsidiarythis Acquisition Integrates Immunogenae S Adc Pipeline Into Abbvieae S Oncology Portfolioaiming To Advance Targeted Cancer Therapies And Improve Patient Outcomes
No conferences found for this company.
| Company Name | Immunogen Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
